MassMutual Private Wealth & Trust FSB Acquires 665 Shares of Eli Lilly and Company $LLY

MassMutual Private Wealth & Trust FSB grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,934 shares of the company’s stock after buying an additional 665 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Eli Lilly and Company were worth $27,871,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LLY. Harbor Investment Advisory LLC grew its position in Eli Lilly and Company by 1.6% in the fourth quarter. Harbor Investment Advisory LLC now owns 10,048 shares of the company’s stock worth $10,799,000 after acquiring an additional 155 shares in the last quarter. Lynch & Associates IN raised its position in Eli Lilly and Company by 2.3% during the fourth quarter. Lynch & Associates IN now owns 8,738 shares of the company’s stock valued at $9,391,000 after purchasing an additional 200 shares during the period. CWA Asset Management Group LLC lifted its stake in shares of Eli Lilly and Company by 14.5% in the 4th quarter. CWA Asset Management Group LLC now owns 6,719 shares of the company’s stock valued at $7,221,000 after purchasing an additional 849 shares during the last quarter. Retirement Wealth Solutions LLC lifted its stake in shares of Eli Lilly and Company by 12.8% in the 4th quarter. Retirement Wealth Solutions LLC now owns 185 shares of the company’s stock valued at $199,000 after purchasing an additional 21 shares during the last quarter. Finally, Aventura Private Wealth LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $4,150,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 Phase 3: Lilly’s triple‑agonist retatrutide showed large A1C reductions and up to ~16.8% weight loss at 40 weeks — a potential blockbuster that expands Lilly’s obesity/diabetes franchise and supports long‑term revenue upside. Lilly PR Newswire
• Positive Sentiment: ADorable‑1 pediatric trial: Positive topline results for EBGLYSS in moderate‑to‑severe atopic dermatitis pediatric patients widen Lilly’s immunology pipeline and add another potential near‑term commercial opportunity. InsiderMonkey: ADorable‑1
• Positive Sentiment: High‑profile endorsement: Jim Cramer publicly said “buy” on Lilly, which can boost retail demand and sentiment in the near term. Yahoo Finance: Cramer
• Neutral Sentiment: Pipeline breadth: Lilly advanced non‑GLP‑1 programs (digital sleep tech in early Alzheimer’s, a new diabetes candidate in Japan, and a master IBD trial), which diversify long‑term growth but have limited immediate revenue impact. TipRanks: Digital Sleep Tech
• Negative Sentiment: Analyst downgrades and rating cuts: Recent downgrades (HSBC and others) have pressured sentiment and contributed to near‑term share weakness. AmericanBankingNews: Analyst Downgrade
• Negative Sentiment: Competitive and safety concerns: Novo Nordisk won FDA clearance for a higher‑dose Wegovy (raising competitive risk in obesity), and some reports flagged an unusual skin reaction/tolerability signal for retatrutide — both factors that can temper uptake forecasts and invite closer regulatory/physician scrutiny. Blockonomi: Wegovy dose Proactive: Retatrutide side‑effect note

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Bank of America decreased their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,313.00 price target on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Daiwa Securities Group increased their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Scotiabank restated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Trading Down 1.3%

NYSE LLY opened at $905.30 on Monday. The stock has a market cap of $855.35 billion, a PE ratio of 39.45, a PEG ratio of 1.05 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company’s 50-day moving average price is $1,023.17 and its 200-day moving average price is $959.29. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter last year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.